14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of QURE
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

uniQure N.V. stock price ended at $4.56 on Wednesday, after losing 4.00%.
(Updated on Apr 24, 2024)

Sell candidate since Feb 29, 2024 Loss -20.70% PDF

The uniQure N.V. stock price fell by -4.00% on the last day (Wednesday, 24th Apr 2024) from $4.75 to $4.56. During the last trading day the stock fluctuated 6.70% from a day low at $4.48 to a day high of $4.78. The price has fallen in 7 of the last 10 days and is down by -9.16% for this period. Volume has increased on the last day by 252 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 566 thousand shares were bought and sold for approximately $2.58 million.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $4.27 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -16.82% during the next 3 months and, with a 90% probability hold a price between $3.56 and $4.97 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

QURE Signals & Forecast

There are few to no technical positive signals at the moment. The uniQure N.V. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $4.70 and $5.05. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Wednesday, March 27, 2024, and so far it has fallen -15.71%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for uniQure N.V. stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.300 between high and low, or 6.70%. For the last week, the stock has had daily average volatility of 3.91%.

uniQure N.V. is oversold on RSI14 (22). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (QURE) For The Upcoming Trading Day Of Thursday 25th

For the upcoming trading day on Thursday, 25th we expect uniQure N.V. to open at $4.61, and during the day (based on 14 day Average True Range), to move between $4.33 and $4.79, which gives a possible trading interval of +/-$0.230 (+/-5.04%) up or down from last closing price. If uniQure N.V. takes out the full calculated possible swing range there will be an estimated 10.07% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $5.17, some $0.610 (13.38%) from the current price of $4.56, our system finds the risk reward not very attractive.

Is uniQure N.V. stock A Buy?

uniQure N.V. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.675 Sell Candidate Unchanged

Predicted Opening Price for uniQure N.V. of Thursday, April 25, 2024

Fair opening price April 25, 2024 Current price
$4.61 ( 1.02%) $4.56

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for QURE

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.91 7.60 %
R2 4.79 5.09 %
R1 4.72 3.54 %
Current price: 4.56
Support S1 4.49 -1.49 %
S2 4.42 -3.04 %
S3 4.31 -5.56 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.32 16.67 %
R2 5.20 14.04 %
R1 5.17 13.38 %
Current price 4.56
Support S1 0 .
S2 0 .
S3 0 .

FAQ

What is the symbol for uniQure N.V. Stock and on which exchange is it traded?
The symbol for uniQure N.V. is QURE and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell uniQure N.V. Stock?
uniQure N.V. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy uniQure N.V. Stock?
uniQure N.V. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy uniQure N.V. Stock.

What's the current price of uniQure N.V. Stock?
As of the end of day on the Apr 24, 2024, the price of an uniQure N.V. (QURE) share was $4.56.

What is the 52-week high and low for uniQure N.V. Stock?
The 52-week high for uniQure N.V. Stock is $22.48 and the 52-week low is $4.48.

What is the market capitalization of uniQure N.V. Stock?
As of the Apr 24, 2024, the market capitalization of uniQure N.V. is 218.143M.

When is the next earnings date for uniQure N.V.?
The upcoming earnings date for uniQure N.V. is May 14, 2024.
Click to get the best stock tips daily for free!

About uniQure N.V.

uniQure N.V. uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas... QURE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT